retatrutide glp-1 gip glucagon triple agonist receptor Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight Calling retatrutide a “GLP-3” is
Description
Personalized treatment approaches according to specific phenotyping and genotyping data are awaited to increase therapeutic benefits
Those qualifying conditions include type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, cardiovascular disease, polycystic ovary syndrome, and non-alcoholic fatty liver disease
Power, E
One note before we go further
Mechanism of Action GLP-1 agonists exert their effects through multiple mechanisms, all of which contribute to their therapeutic benefits
